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Background:miRNAs exert important roles during osteoblast proliferation and differentiation.
Results:miR-322 induces expression of osteogenic genes by down-regulation of expression ofTob2, which binds to the 3-UTR
of Osx and modulates its degradation.
Conclusion:miR-322 and its target Tob2 are regulators of osteogenesis through control of OsxmRNA degradation.
Significance:Wehave identified amiRNA-transcription factor network that allows fine-tuning of the osteoblast differentiation
program.
Osteogenesis depends on a coordinated network of signals
and transcription factors such as Runx2 and Osterix. Recent
evidence indicates that microRNAs (miRNAs) act as important
post-transcriptional regulators in a large number of processes,
including osteoblast differentiation. In this study, we performed
miRNA expression profiling and identified miR-322, a BMP-2-
down-regulated miRNA, as a regulator of osteoblast differenti-
ation. We report miR-322 gain- and loss-of-function experi-
ments in C2C12 and MC3T3-E1 cells and primary cultures of
murine bone marrow-derived mesenchymal stem cells. We
demonstrate that overexpression of miR-322 enhances BMP-2
response, increasing the expression ofOsx and other osteogenic
genes. Furthermore, we identify Tob2 as a target of miR-322,
and we characterize the specific Tob2 3-UTR sequence bound
by miR-322 by reporter assays. We demonstrate that Tob2 is a
negative regulator of osteogenesis that binds andmediates deg-
radation ofOsxmRNA. Our results demonstrate a newmolecu-
lar mechanism controlling osteogenesis through the specific
miR-322/Tob2 regulation of specific target mRNAs. This regu-
latory circuit provides a clear example of a complex miRNA-
transcription factor network for fine-tuning the osteoblast dif-
ferentiation program.
Skeletal development depends on the activity of osteoblasts
that derive from condensations of mesenchymal cells. In addi-
tion, bone is constantly remodeled throughout life, and it
requires stringent control of a program of gene activation and
suppression in response to physiological signals. Understand-
ing this regulatory mechanism is important for developing new
strategies to treat pathological states such as osteoporosis and
osteosclerosis. For the specification of mesenchymal cells to
distinct terminal phenotypes, cohorts of tissue-specific tran-
scription factors and coregulators mediate the expression of
genes required for the functions of a particular differentiated
tissue. Molecular and genetic research has identified Osterix
(Osx), Runx2, Dlx5, Msx2, and ATF4, among others, as impor-
tant transcription factors essential for osteoblast differentiation
(1, 2). Osx and Runx2 have been widely accepted as master
osteogenic factors because neither Runx2- nor Osx-null mice
form mature osteoblasts (3, 4).
Osteoblast lineage specification andmaturation of osteopro-
genitors are also controlled by multiple extracellular ligands.
Bone morphogenetic proteins (BMPs)3 belong to the TGF-
superfamily and, together with Wnt proteins, are the main
extracellular cues involved in the activation of skeleton-related
genes for formation of cartilage and bone. BMP signals are
transduced by Smad proteins and have been shown to stimulate
Runx2 and Osx in vitro and in vivo (5–10).
Recently, microRNAs (miRNAs) have emerged as important
regulators in various developmental, physiological, and patho-
logical conditions, including cell differentiation and function
(11). miRNAs are small noncoding RNAs that mediate transla-
tional inhibition or degradation of the transcript by binding to
complementary sites in the 3-UTRs or coding regions of target
mRNAs (12). Recent studies indicate that miRNAs are impor-
tant players during osteogenic differentiation, and the identifi-
cation of new miRNAs characterizing genetic and metabolic
abnormalities provides new approaches for treatment of dis-
eases (13–19). It has been shown that depletion of miRNAs in
the osteoblast lineage through conditional ablation of theDicer
gene causes evident skeletal phenotypes (20). Interestingly, pre-
vious studies have shown differential requirements of miRNA
control at early and late steps of osteogenesis, suggesting that
miRNAs are required for embryonic bone development as well
as for bone homeostasis in the adult skeleton.
BMP and TGF- are known to regulate miRNA biogenesis
through ribonuclease 3, also known as Drosha (21). BMP-2 has
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been shown to down-regulate a cohort of miRNAs that target
inhibitors of multiple osteogenic pathways in premyogenic
cells, including BMP and Wnt receptors and their ligands as
well as transcriptional regulators and MAPK signaling compo-
nents (15, 22–26). Interestingly, the few miRNAs that are
strongly up-regulated by BMP-2 in premyogenic cells target
essential factors formuscle cell differentiation, thereby repress-
ing their differentiation to myocytes.
In this study, we characterized miR-322, a novel BMP-2-
down-regulated miRNA, and investigated its effects on osteo-
blast differentiation. We identified Tob2 as its target and
showed that Tob2 regulated OsxmRNA degradation. We pro-
pose a regulatory mechanism in which miR-322/Tob2 controls
Osx degradation and allows an integrated post-transcriptional
control of multiple osteogenic genes.
EXPERIMENTAL PROCEDURES
Plasmids, Reagents, and Antibodies—pME18S-hTob2 was
provided byDr. T. Yamamoto. pFLAG-CMV-hCPEB4was pro-
vided byDr. R.Méndez. To determine the target region ofmiR-
322, the 3-UTR of the mouse Tob2 cDNA was amplified from
genomic DNA using primers 5-TGCTGAAGTCTAGAGAC-
CATCAGGCTT-3 and 5CTCCCATCTAGAAAAAGGAT-
TCGCCCAGG-3 for the wild type and primers 5-TGCTGA-
AGTCTAGAGACCATCAGGCTT-3 and 5AGAGTGGTC-
TAGATGTCAATTCGTGCACC for the mutant construct
and cloned between theXbaI sites of the pRL-SV40 vector (Pro-





CCUCCC-3. Cox2- and Id1-luciferase reporter constructs
were described previously (27, 28). BMP-2 was from R&D Sys-
tems (Minneapolis, MN) and used at a final concentration of 2
nM. Actinomycin D (Sigma) was used at final concentration of
10 g/ml. The following antibodies were used at 1:1000 for
immunoblotting: anti-Osx (Abcam, Cambridge, UK); anti-
Smad1 and anti-phospho-Smad (Cell Signaling, Beverly, MA);
anti-Tob2 and anti-FLAG (Sigma); and anti--tubulin (Sigma).
Immunocomplexes were visualized with a horseradish peroxi-
dase-conjugated anti-rabbit or anti-mouse IgG antibody
(1:10,000), followed by incubation with ECLWestern blot rea-
gent (GE Healthcare). Chemiluminescent image capture of
immunoblots was performed with the Fujifilm LAS 3000
device. Quantification of protein expression was performed
using FujifilmMultiGauge software and is expressed as relative
values using -tubulin as a control.
Cell Culture, Differentiation, and Transfections—Bone mar-
row-derivedmesenchymal stemcells (BM-MSCs)were isolated
and cultured as described previously (8) and treated for 24 h
with BMP-2 (2 nM) before miRNA isolation. C2C12 and HeLa
cell lines were maintained as described previously (9). The
MC3T3-E1 cell line was maintained in -modified Eagle’s
medium supplemented with 10% FBS. To induce C2C12 cell
differentiation, the medium was replaced with DMEMwithout
serum, andBMP-2 (2 nM)was added. To induceMC3T3-E1 cell
differentiation, the medium was replaced with -modified
Eagle’s medium with 10% FBS, 50 M ascorbic acid, and 5 mM
-glycerophosphate. Cells were transiently transfected using
Lipofectamine RNAiMAX (Invitrogen) for miRNAs and Lipo-
fectamine LTX (Invitrogen) for cotransfection with plasmids.
Transfection efficiency was assessed by GFP or BLOCK-iT
Alexa Fluor Red fluorescent control (Ambion, Paisley, United
Kingdom). Pre-miRTM andAnti-miRTM (Ambion)were used at
final concentration of 20 nM.
Microarray and RT-qPCRAnalysis—Total RNAwas isolated
from C2C12 cells, MC3T3-E1 cells, or BM-MSCs using the
Ultraspec RNA isolation system (Biotecx, Houston, TX). 3 g
of total RNA was reverse-transcribed using a High Capacity
cDNA reverse transcription kit (Applied Biosystems). miRNAs
were isolated using a mirVana miRNA isolation kit (Applied
Biosystems), and reverse transcription was performed using a
TaqMan microRNA reverse transcription kit (Applied Biosys-
tems). Initial miRNA screening was performed using TaqMan
Array Rodent MicroRNA B Card v3 (Applied Biosystems).
miRNA qPCRs were performed using specific probes (TaqMan
microRNA assays). All quantitative PCRs were carried out
using the ABI Prism 7900HT fast real-time PCR system and the
TaqMan 5-nuclease probe method (Applied Biosystems).
mRNA transcriptswere normalized toGAPDHexpression, and
miRNA transcripts were normalized to U6 expression.
Luciferase Reporter Assays—Cells were transfected for 8 h
without serum and treated with BMP-2 for 16–24 h. Luciferase
activities were quantified using the luciferase assay system or
theRenilla luciferase assay system (Promega). Luciferase values
were normalized using -galactosidase detection kit II (Clon-
tech, Palo Alto, CA).
Lentiviral Transduction—LentimiRa-GFP-mmu-mir-322 and
Lenti-IIII-mir-GFP control virus (ABM Inc., Richmond, British
Columbia, Canada) were used for BM-MSC transduction at a
multiplicity of infection of 1, and efficiency was controlled by
the GFP coexpressed in the same construct. Polybrene (Sigma)
was used at final concentration of 2 g/ml to enhance viral
infection. Puromycin was used to select infected cells at 2
g/ml. Selected MSCs were cultured for 5 days in osteogenic
differentiating medium (DMEM supplemented with pyruvate,
glutamine, penicillin/streptomycin, 50 g/ml ascorbic acid,
and 5 mM -glycerophosphate).
RNA Pulldown Assay—HeLa cells were transfected for 4 h
using Lipofectamine LTX. GFP was used as a transfection con-
trol. Cells were harvested by adding lysis buffer (50mMTris (pH
7), 100 mM KCl, 5 mM MgCl2, 10% glycerol, 1 mM DTT, 0.2%
Nonidet P-40, and protease and phosphatase inhibitors).
Lysates were centrifuged for 5 min at 16,000  g. Yeast RNA
(0.5 mg/mg of protein; Sigma) was added to the supernatant to
block nonspecific binding. Biotinylated RNAs were denatured
at 65 °C for 5 min and cooled for 20 min in 10 mM Tris (pH 7),
100 mM KCl, and 10 mM MgCl2. 0.5 g of each RNA was incu-
batedwith cell lysates for 60min at 4 °C, including 200 units/ml
RNasin (Promega). 25 l of streptavidin-Sepharose (GE
Healthcare) was added and further incubated at 4 °C for 60min.
Beads were washed five times with lysis buffer. Bound proteins
were detected by Western blotting.
Analysis ofmiRNATarget Data Set—In silico putative targets
were screened for each of the differentially expressed miRNAs
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by three different algorithms: DIANA-microT v5.0 (29),
miRanda (30), and TargetScan 6.2 (31).
Statistical Analysis—Statistical analysis was performed using
Student’s t test or two-way analysis of variance, followed by
Bonferroni multiple-comparison tests. Quantitative data are
presented as means  S.E. Differences were considered signif-
icant at p values of 0.05.
RESULTS
miRNA Expression Profile during BMP-2-induced Osteoblast
Differentiation—To identify miRNAs whose expression is
altered during osteoblast differentiation, C2C12 cells were
treated with BMP-2 (2 nM) in medium without serum for 8 h.
Independent experimentswere performedunder the same con-
ditions, and amiRNA expression profile was obtained (Fig. 1A).
FIGURE 1. Expression profile of miRNAs during osteoblast differentiation. A, miRNA array expression data from C2C12 cells treated with BMP-2 for 8 h. Red
denotes higher expression, and green denotes lower expression relative to expression in control cells. Only miRNAs with a 2-fold reduction in expression are
shown. B and C, expression of miR-30a, miR-206, and miR-322 was analyzed during osteoblast differentiation. Time course experiments were performed with
2 nM BMP-2 treatment with (B) or without (C) 10% fetal bovine serum. The indicated miRNAs were isolated from C2C12 cells cultures as described under
“Experimental Procedures,” measured by RT-qPCR, normalized to U6 RNA, and plotted as relative expression to time 0 (means  S.E. of five independent
experiments). BM-MSCs (D) and MC3T3-E1 cells (E) were treated with BMP-2 in the absence of serum for 24 h, and the indicated miRNAs were measured by
RT-qPCR. F, MC3T3-E1 cells were treated or not with differentiation medium for 10 days, and the indicated miRNAs were measured by RT-qPCR in five
independent experiments. *, p  0.05; **, p  0.01; ***, p  0.001.
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In agreement with previous results, global analysis indicated
that most of the significantly changed miRNAs were down-
regulated in response to BMP-2 (13, 14). For instance, miR-206
was shown to decrease during C2C12 cell differentiation (25),
andmiR-30 familymembers are also down-regulated byBMP-2
(32).
To verify these results, miR-30a,miR-206, andmiR-322were
chosen for further study. These miRNAs were expressed at rel-
atively high levels in C2C12 cells (supplemental Table 1). To
confirm the array data, kinetic assays of BMP induction in the
presence and absence of serum were performed, and the
expression of selected miRNAs was detected by qPCR. Time
course results were consistent with array data: miR-30a, miR-
206, and miR-322 all steadily decreased after BMP-2 addition
(50–60% decrease at 8 and 24 h for miR-206 and miR-322)
(Fig. 1B). Down-regulation of miRNA expression to a similar
extent was also observed in cells cultured in the absence of
serum (Fig. 1C). We extended our observations to primary cul-
tures of murine BM-MSCs and MC3T3-E1 cells. BMP-2 treat-
ment of BM-MSCs or MC3T3-E1 cells for 24 h caused similar
miR-322 expression down-regulation, whereas miR-30a
expression remained not significantly altered with respect to
the miR control (Fig. 1,D and E). We also analyzed differentia-
tion of MC3T3-E1 cells in medium containing ascorbic acid
and -glycerophosphate. In this case, although differentiation
led to similar effects as BMP-2 addition on miR-30a and miR-
206 expression levels, it induced a significant increase in miR-
322 levels instead (Fig. 1F).
Effects of miR-30a, miR-206a, and miR-322 on Osteoblast
Differentiation—To determine whether the selected miRNAs
affect osteoblast differentiation, C2C12 cells were transfected
with mimics of miR-30a, miR-206, and miR-322 and treated
with BMP-2 for 16 h. Their effects were first assessed by char-
acterizing the mRNA expression levels of the main osteoblast-
determining transcription factors. It is well known that BMP
addition to C2C12 cells stimulates expression of known osteo-
genicmarkers (1, 2, 4, 9, 33). Overexpression ofmiRNAmimics
produced a significant increase in Osx, Runx2,Msx2, osteocal-
cin, and IbspmRNA levels by miR-322 and increases in Runx2
and Ibsp by miR-206 (Fig. 2A). Upon BMP-2 stimulation,
ectopic expression of a miR-322 mimic resulted in a significant
accumulation ofOsx,Runx2,Msx2, and IbspmRNA levels com-
pared with expression of a control miRNA mimic. miR-30a
transfection reduced both basal and BMP-stimulated Dlx5
mRNA expression. We also analyzed the effects of miRNAs at
the protein level (Fig. 2B). Although Osx protein expression
increased significantly aftermiR-322 transfection,miR-206 and
miR-30a overexpression led to an Osx decrease, possibly indi-
cating negative osteoblast regulation, in accordance with previ-
ous work (13, 32). C2C12 cells differentiate into myoblasts and
generatemultinuclearmyotubes in the presence of low levels of
serum.However, BMP-2 is able to transdifferentiate them from
the myoblast to the osteoblast lineage (34). To investigate
whether miR-322 can also influence their myogenic differenti-
ation, C2C12 cells were transfected with miR-322 or miR con-
trol and followed up for myotube formation (Fig. 2C). Experi-
ments revealed a complete lack of myotube formation up to 4
days in miR-322-overexpressing cells.
We also analyzed overexpression of miRNA mimics in
MC3T3-E1 cells, an osteoblast cellular model independent of
BMP activation. Similar to C2C12 cells, Osx, Runx2, andMsx2
mRNA levels were significantly increased bymiR-322 (Fig. 3A).
Altogether, these results suggested that miR-322 might be
important for osteogenic differentiation and led us to investi-
gate its molecular mechanisms of action.
We then performed miR-322 loss-of-function experiments.
Consistently, transfectionofPre-miR-322 led to increased levelsof
miR-322, whereas transfection of Anti-miR-322 led to a 40%
decrease in expression of endogenous miR-322 (supplemental
Fig. S1). Therefore, Anti-miR-322 was transfected in cells in the
presence or absence of BMP-2 to assess the effect on osteogenic
genes. The decrease in miR-322 levels led to a significantly lower
induction ofOsx and Runx2mRNAs by BMP-2 (Fig. 3B).
Lack of Direct Interaction between miR-322 and the Smad
Pathway—Smad proteins have been found to play critical roles
in osteoblast differentiation induced by BMPs (7). The above
results suggested that miR-322 was able to increase expression
of osteogenic genes in response to BMP-2. Thus, we decided to
determine whether miR-322 directly modulates Smad phos-
phorylation and signaling by performing time course experi-
ments of BMP-2 activation. Ectopic expression of miR-322 led
to a slight decrease in Smad1 expression that became signifi-
cant after 8 h of BMP-2 addition (supplemental Fig. S2A). How-
ever, immunoblotting showed no significant changes in the
ratio between phosphorylated and total Smad1 levels (supple-
mental Fig. S2A , left panel). These results suggest that the effect
of miR-322 in osteoblast differentiation is not likely related to a
direct change in phospho-Smad1 levels. In parallel, Smad1 and
phospho-Smad1 levels were evaluated by immunoblotting after
transfection with Anti-miR-322 and BMP-2 addition. No sig-
nificant changes were observed in phospho-Smad activation
(supplemental Fig. S2B).
Tob2 Is aTarget ofmiR-322—The essential role of Runx2 and
Osx in bone development led us to analyze the mechanisms
regulated by miR-322 in osteoblast differentiation. Bioinfor-
matic target prediction was carried out using DIANA,
miRanda, and TargetScan prediction software. Putative tar-
geted genes included HoxA10 and Dlx5 (osteogenic transcrip-
tion factors); activin receptors IIA and IIB, Smurf1, Smad7, and
Smad1 (BMP signaling); and Cdc25A and Tob2 (cell prolifera-
tion and differentiation) (supplemental Table 2). These targets
were experimentally validated after miRNA mimic transfec-
tion. The results showed that the expression of Tob2 mRNA
and the induction of Tob2 and Smad7 mRNAs by BMP-2
(6-fold increase for Smad7) were significantly decreased inmiR-
322-transfected cells, whereas no significant differences were
found for miR-30a and miR-206 assays (Fig. 4A). Smurf1mRNA
levelswerenot altered in any case.Moreover,Anti-miR-322 trans-
fection increased Tob2 mRNA levels, both basal levels and after
BMP-2 addition (Fig. 4B). The results led us to focus on Tob2
regulation by miR-322. Time course experiments in C2C12 cells
showed that, in correlationwith themiR-322 expression decrease,
BMP-2 addition promoted higher levels of Tob2 mRNA expres-
sion (supplemental Fig. S3).We also analyzed whether changes in
Tob2 mRNA in response to miR-322 correlated with changes in
Tob2 protein levels. Quantification of Western blot analysis
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revealed a significant decrease inTob2 levels after transfectionof a
miR-322 mimic and a significant increase after Anti-miR-322
transfection (Fig. 4C). To confirm our previous results, we per-
formed lentivirus-mediated overexpression experiments in BM-
MSCs. Cells were transduced with either a lentiviral construct
expressing miR-322 or a control, and mRNA was extracted after
10daysof culture inosteogenicmedium(Fig. 4D).Consistentwith
the data from C2C12 cell cultures, miR-322 accumulation
repressed Tob2 and Smad7 expression and induced significantly
higher Osx mRNA levels compared with cells transduced with a
lentiviral control. Taken together, these results provide evidence
that miR-322 negatively regulates Tob2 expression in mesenchy-
mal cells.
We attempted to confirm these observations using luciferase
reporter constructs to examine whether miR-322 can directly
regulate Tob2 expression. miRNAs are able to repress gene
expression by binding to seed site sequences located within the
3-UTR of mRNA (12). We determined the presence of a puta-
FIGURE 2. miR-322 enhances Osx, Msx2, and Runx2 expression. A, C2C12 cells were transfected with the indicated miRNA mimics without serum for 8 h and
treated with BMP-2 overnight. RT-qPCR for the indicated genes was performed, and GAPDH was used as an internal control. Results are plotted as expression
relative to untreated Pre-miR control-transfected cells (means  S.E. of four to nine independent experiments). B, C2C12 cells were transfected with the
indicated miRNA mimics and treated with 2 nM BMP-2 for 24 h, and Osx and tubulin were detected by immunoblotting (left panel). Quantification of the results
of three independent experiments is shown (right panel). C, miR-322 mimic-transfected C2C12 cells were maintained in medium without serum for 4 days, and
myotube progression was compared with Pre-miR control-transfected cells. *, p  0.05; **, p  0.01; ***, p  0.001.
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tive target region of miR-322 at position1769 ofTob2mRNA
using miRNA target prediction tools. We generated Renilla
luciferase reporter constructs containing the wild-type Tob2
3-UTR or a construct with the miR-322-binding sequence
mutated (Fig. 5A). The luciferase activity of the wild-type Tob2
3-UTR construct was significantly inhibited after cotransfec-
tion with miR-322 in C2C12 or MC3T3-E1 cells (Fig. 5, B and
C). Furthermore, the mutant Tob2 3-UTR construct lacking
the possible binding region of miR-322 was refractory to the
decrease in luciferase activity after miR-322 mimic cotransfec-
tion. These results provide evidence that miR-322 acts as an
inhibitor of Tob2 mRNA expression through binding to a
region located in its 3-UTR.
Tob2 Accelerates Decay of Osx mRNA Levels—Tob1-defi-
cientmice have a higher bonemass due to an increased number
of osteoblasts and an accelerated bone formation rate (35).
Thus, Tob proteins act as negative regulators of bone forma-
tion, although the mechanisms of this regulatory role are
mostly unknown. We then further examined how miR-322/
Tob2 increases osteoblast-related genes and their interaction
with the BMP-Smad pathway. First, we analyzed luciferase
activity using Id1 and Cox2 promoter constructs with strong
responsiveness to BMP signaling, previously generated in our
group (27, 28). Luciferase reporter constructs were cotrans-
fected with constructs overexpressing Tob2, miR-322, or Anti-
miR-322. No major differences in luciferase activities were
observed (supplemental Fig. S4).
Previous studies identified Tob not only as a general regula-
tor of mRNA decay (36, 37) but also as a specific regulator by
binding to CPEB2–4 (cytoplasmic polyadenylation element-
binding protein) and recruitingCnot7 deadenylase to the target
mRNAs (38). To analyze the ability of Tob2 to regulate the
mRNA degradation of specific genes, we performed mRNA
decay assays. The mRNA levels of C2C12 cells overexpressing
Tob2, miR-322, or miR control were quantified by qPCR at
different time points after treatment with actinomycin D (a
known inhibitor of mRNA synthesis). mRNA expression of the
genes analyzedwas alreadymodified by the transfections before
actinomycin D treatment (Fig. 6A). Overexpression of Tob2
reduced the basal levels of expression of Osx, Runx2, Smad7,
and Dlx5. Moreover, overexpression of miR-322 also led to
increased levels ofOsx and Runx2mRNAs. In themRNA decay
assays after actinomycin D addition, overexpression of Tob2
reduced the half-live of Osx transcripts (significant reduction
after 1 h).Moreover, accumulation ofmiR-322 led to significant
stabilization of Osx mRNA and Runx2 to a lesser extent (Fig.
6B). Smad7, Dlx5, and Msx2 mRNA degradation was not sig-
nificantly altered in any case. These data indicate that Tob2
modifies the mRNA decay of specific target genes. To further
our observations, we performed the same experiments in
MC3T3-E1 cells. Expression of the genes analyzed was also
already modified by transfection of the miR-322 mimic. Osx,
Runx2, Dlx5, and Msx2 mRNA expression was significantly
increased (Fig. 7A). mRNA decay assays after actinomycin D
addition further demonstrated that overexpression of miR-
322 led to a significantly slower rate of Osx mRNA decay (Fig.
7B). In view of our results, we hypothesized that Osx mRNA
could be a direct target bound by Tob2 and CPEB2–4 and, as a
consequence, specifically decayed. We analyzed 3-UTR
sequences, and interestingly, Osx has compatible secondary
structures containing a similar stem-loop structure bound by
CPEB2–4 (supplemental Fig. S5) (39). We performed RNA
FIGURE 3. Effects of miR-322 in MC3T3-E1 cells and antisense inhibitor for
miR-322 in C2C12 cells. A, MC3T3-E1 cells were transfected with the indi-
cated miRNA mimics for 8 h and treated with differentiation medium overnight.
RT-qPCR for the indicated genes was performed, and GAPDH was used as an
internal control. Results are plotted as expression relative to untreated Pre-miR
control-transfected cells (means  S.E. of four to six independent experiments).
B, C2C12 cells were transfected for 8 h with Anti-miR-322 and treated with BMP-2
overnight. The indicated mRNAs were measured by RT-qPCR, normalized to
GAPDH, and expressed as relative expression (means  S.E. of four to five inde-
pendent experiments). *, p  0.05; **, p  0.01; ***, p  0.001.
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pulldown assays using two oligonucleotides corresponding to
distinct stem-loop sequences found in the 3-UTR of Osx
mRNA and a control RNA. Either expressed alone or in com-
bination, CPEB4 and Tob2 were able to bind specifically the
Osx 3-UTR sequences (Fig. 7C).
Taken together, these results strongly suggest that miR-322
increasesOsxmRNA expression via inhibition of Tob2mRNA.
Furthermore, our data suggest that the well known effects of
Tob proteins on bone development and homeostasis could
derive, at least partly, from the role of Tob in the specific deg-
radation and decay of OsxmRNA.
DISCUSSION
In our study, we identified miR-322 as a miRNA down-reg-
ulated by BMP-2. We have demonstrated for the first time that
miR-322 is involved in osteoblast differentiation by targeting
FIGURE 4. miR-322 inhibits Tob2 expression. C2C12 cells were transfected with selected miRNA mimics (A) or miR-322 inhibitor (B) without serum for 8 h and
treated with BMP-2 overnight. Tob2, Smurf1, and Smad7 expression was detected by RT-qPCR, normalized to GAPDH, and expressed relative to the miR control
transfection. All values represent the means  S.E. of four to seven independent experiments. C, C2C12 cells were transfected with 20 nM miRNA mimic or
inhibitor, and Tob2 and tubulin were detected by Western blotting (left panel). The right panel shows the relative Tob2 levels normalized to tubulin expression.
D, BM-MSCs were infected with viral particles containing mmu-miR-322 or miR control overnight. Transduced cells were selected with puromycin for 4 days as
described under “Experimental Procedures.” Cells were cultured until confluence with osteogenic medium and collected to analyze the indicated mRNAs by
RT-qPCR. Results were normalized to GAPDH and plotted as relative expression (means  S.E. of three to four independent experiments). *, p  0.05; **, p 
0.01; ***, p  0.001.
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Tob2. We reported that overexpression of miR-322 decreases
Tob2mRNA and protein expression and leads to increased lev-
els of the transcription factor Osx. Furthermore, we have dem-
onstrated direct evidence of the binding site of miR-322 in the
Tob2 3-UTR. We propose a molecular description of the
mechanism whereby the osteogenic master gene Osx is con-
trolled post-transcriptionally through a mechanism driven by
miR-322/Tob2. More importantly, our findings strongly sug-
gest that control of specific mRNA decay is relevant in bone
development and homeostasis.
miR-322 has been previously studied together with miR-503
in myogenesis as promoters of cell cycle quiescence and differ-
entiation by down-regulation of Cdc25A (40). Expression of
miR-322 (which is clustered with miR-503, miR-351, and miR-
450) is highly enriched in fibroblasts and cells of themesenchy-
mal lineage (microRNA.org). Our findings add a new role and a
novel target of miR-322 during osteoblast differentiation. Our
results also show that, after differentiation by BMP-2, the miR-
322 level progressively decreases inC2C12 andMC3T3-E1 cells
and primary cultures of BM-MSCs. We have mentioned the
up-regulated expression of osteogenic transcription factors
during BMP-2 treatment. Then, miR-322, by means of Tob2
down-regulation, adjusts the expression levels of some of these
factors, particularly Osx. This profile seems to allow the tran-
scriptional up-regulation of the osteogenic transcription fac-
tors, whereas miR-322 may later exert a regulatory mechanism
that allows fine-tuning of bone homeostasis.
Our results suggest that the miR-322/miR-351/miR-450/
miR-503 cluster is repressed by the addition of BMP-2 (miR-
503 was also highly down-regulated in our screen). Smad pro-
teins, the signal transducers of the BMP pathway, have been
found to regulate miRNA expression through both transcrip-
tional and post-transcriptional mechanisms (41). Like mRNAs,
miRNAs are transcribed by RNA polymerase II and have been
shown to be subjected to either positive or negative transcrip-
tional regulation through Smad-containing transcriptional
enhancers located in the specific miRNA promoter (41). In
addition, Smad proteins have been shown to regulate specific
miRNA processing and maturation through interaction with
the Drosha complex (21). These miRNAs require a CAGAC
sequence at the 3-end of their mature miRNA sequence to
bind and be regulated by the Smad-Drosha complex (42).
Because none of the mature miRNAs corresponding to the
miR-322 cluster contain this CAGAC sequence, it is likely that
regulation of the miR-322 cluster depends on direct transcrip-
tional repression by Smad proteins, as has been demonstrated
in other miRNAs (43, 44).
The cellular levels of phosphorylated Smad1 were not signif-
icantlymodified by the addition of eithermiR-322 orAnti-miR-
322.Notably, we found that Smad7 is also a target ofmiR-322 in
C2C12 cells and BM-MSCs, and it is well known that Smad7 is
induced by BMP-2 as a negative feedback loop. Smad7 belongs
to the inhibitory Smad (I-Smad) family, the main inhibitory
mechanism of the cooperative signaling of R-Smad and Co-
Smad proteins (45). Moreover, Tob proteins have been shown
to associate with the MH2 domains of Smad proteins and to
repress Smad transcriptional complexes (35). These twomech-
anisms may contribute, in an additive way, to a lower BMP
response. Nevertheless, analysis of the quantitative role of
Smad7 and Tob2 repression in the induction ofOsx and Runx2
transcripts by miR-322 also awaits further study.
AlthoughmRNA decay has been shown to be highly relevant
in a number of physiological processes (46), there are few exam-
ples of this post-transcriptional regulatory mechanism in bone
development. For instance, polymorphisms in the 3-UTR of
FIGURE 5. Tob2 is a direct target of miR-322. A, schematic representation of
the alignment of the mouse Tob2 mRNA 3-UTR predicted to be targeted by
miR-322. Mutations generated within the region corresponding to the seed
sequence were included in the mutant Tob2 3-UTR construct. C2C12 (B) or
MC3T3-E1 (C) cells were cotransfected with the Renilla luciferase reporter
plasmid carrying the wild-type or mutant (MUT) Tob2 3-UTR and miR-322 or
miR control, respectively. After 8 h, cells were cultured until confluence for
16 h, and luciferase activity was analyzed and normalized to -galactosidase
expression. Relative luciferase activities are expressed as means  S.E. for
triplicates from four to six independent experiments. ***, p  0.001.
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VDR lead to differential mRNA decay and increased risk of
osteoporosis (47). In addition, it has also been shown that AU-
rich elements mediate stabilization of collagenase-3 mRNA in
osteoblasts (48). Tob1 and Tob2 proteins constitute a Tob sub-
family and belong to the BTG/Tob antiproliferative factor pro-
tein family (49, 50). Tob genes have emerged as key players in
mediating post-transcriptional gene expression by regulating
mRNA deadenylation and therefore cytoplasmic mRNA levels
(51). Our results suggest that new target genes displaying com-
patible Tob-interacting secondary structures at their 3-UTR
could be subjected to specific mRNA repression by Tob family
members, as we suggest here for Osx. These data are in agree-
ment with previous research showing that, although Tob1
knock-outmice are bornwithout apparent phenotypic abnormal-
ities, Tob1-deficient adult mice were shown to have higher bone
mass compared with wild-type mice (35). These data also explain
whyTobdeficiencyenhancesosteoblast activityblockingosteopo-
rosis induced by ovariectomy (52). Furthermore,mice deficient in
Cnot7, the Tob-interacting deadenylase, also exhibit a high bone
mass phenotype and increased responses to BMPs (53).
FIGURE 6. miR-322 stabilizes Osx mRNA via Tob2 repression in C2C12 cells. A and B, C2C12 cells were transfected with Tob2, miR-322, or miR control for 8 h,
cultured overnight, and treated with BMP-2 for 2 h before actinomycin D addition. A, expression of the indicated mRNAs at time 0. Expression of selected genes
is plotted relative to miR control transfection (means  S.E. of six independent experiments). B, actinomycin D was added, and mRNAs were collected at the
indicated times. RT-qPCR was performed using GAPDH as the endogenous control. Data are expressed relative to control transfection mRNA levels at time 0
(means  S.E. of seven to eight independent experiments). *, p  0.05; **, p  0.01; ***, p  0.001.
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FIGURE 7. miR-322 stabilizes Osx mRNA in MC3T3-E1 cells, and Tob2 binds to the Osx 3-UTR. A and B, MC3T3-E1 cells were transfected with miR-322 or miR
control for 8 h and cultured overnight. A, expression of the indicated mRNAs at time 0. Expression of selected genes is plotted relative to miR control
transfection (means  S.E. of four independent experiments). B, actinomycin D was added, and mRNAs were collected at the indicated times. RT-qPCR was
performed using GAPDH as the endogenous control. Data are expressed relative to control transfection mRNA levels at time 0 (means  S.E. of four indepen-
dent experiments). C, HeLa cells were transfected with GFP (control (CTR)), Tob2, CPEB4, or CPEB4 and Tob2 (CT). RNA pulldown assay was performed as
described under “Experimental Procedures,” and the presence of Tob2 and CPEB4 was confirmed by Western blotting. *, p  0.05; **, p  0.01; ***, p  0.001.
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Long C-terminal regions of both Tob1 and Tob2 include
short conserved PAM2motifs, which are not found in the other
BTG/Tob family members. These motifs mediate direct inter-
actions with the poly(A)-binding protein PABPC1 and Cnot7
simultaneously, contributing to the role of Tob1 and Tob2 in
general mRNA deadenylation andmRNA turnover (37). More-
over, it has been shown that Tob proteins can interact with
CPEB2–4 and specifically intensify the rapid decay of particu-
lar transcripts (51). Whereas CPEB1 binds to the cytoplasmic
polyadenylation elements (UUUUUAU) in the 3-UTR of
mRNAs, promoting polyadenylation, CPEB2–4 also bind a
sequence other than the cytoplasmic polyadenylation element.
Their RNA-binding domains recognize mRNAs with specific
secondary structures containing U-rich loops and interact with
single-stranded uridines as well as double-stranded stems pres-
ent in the 3-UTR of the target mRNA (38, 39). Recent studies
showed Tob1 interaction with cytoplasmic CPEB2–4, which
negatively regulate the expression of a target by tethering to
specific mRNA and mediating recruitment of the deadenylase
Cnot7, leading to specific mRNA decay (38). Furthermore, a
previous study showed that CPEB3 binds to the 3-UTR of
AMPA receptor (GluR2) mRNA and negatively regulates its
expression, becoming the only known target of CPEB3 at pres-
ent (39). TheOsx 3-UTR contains secondary structures with a
stem-loop structure similar to those bound by CPEB2–4 (sup-
plemental Fig. S4) (39). Our RNA pulldown analysis showed
that these sequences are directly bound by CPEB proteins and
Tob2. Thus, in view of our results, we hypothesize that Osx
mRNA could be bound by Tob2 and CPEB2–4 and, as a conse-
quence, specifically degraded. Moreover, in silico analysis
showed thatCPEB2–4 are also putative targets of miR-322 and
miR-503, whereas they do not targetCPEB1. This suggests that,
in addition to Tob2, miR-322 could also target CPEB genes to
coordinately regulateOsx expression. Future work is necessary
to discern which CPEB-like proteins are involved in the inter-
action between Tob2 and stem-loop structures in the 3-UTR
of Osx and other osteogenic genes.
In summary, we have demonstrated that down-regulation of
miR-322 in response to BMP-2 acts as a negative regulator of
Osterix expression. We also identified Tob2 accumulation as
an important step in fine-tuning the expression of Osx and
other osteogenic transcription factors during osteoblast differ-
entiation. This novel mechanism highlights the possibility of
exploring new therapeutic approaches targeting Tob proteins
to treat bone diseases.
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